Are annual fine‑needle aspiration biopsies recommended for patients with a goiter?

Annual Needle Biopsies for Goiters: Not Recommended

Annual fine-needle aspiration biopsies are not recommended for patients with goiters. The decision to perform repeat biopsy should be based on specific clinical and ultrasound criteria rather than a fixed time interval, and most benign nodules require only periodic ultrasound surveillance at intervals of 1-4 years, not annual biopsies. 1

Initial Biopsy Indications

The decision to perform an initial FNA should be guided by:

• EU-TIRADS risk stratification combined with nodule size, not simply the presence of a goiter 2, 3
• High-risk (EU-TIRADS 5) nodules ≥10 mm warrant FNA 3
• Intermediate-risk (EU-TIRADS 4) nodules >15 mm should be biopsied 3
• Low-risk (EU-TIRADS 3) nodules require FNA only if ≥20 mm 3
• Very low-risk (EU-TIRADS 2) nodules should not be biopsied unless ≥20 mm and growing 3

All FNA procedures must be performed under real-time ultrasound guidance to improve safety, reliability, and diagnostic accuracy. 2, 3

Surveillance Strategy After Benign Cytology

Following an initial benign FNA result (Bethesda II):

• The risk of subsequent malignancy is only 1-3% in nodules with benign cytology 1, 4
• First follow-up ultrasound should occur at 1-2 years, then every 2-4 years if stable 1
• Some recent evidence supports even longer intervals, with first reassessment at 3 years 1
• Discontinuation of monitoring may be considered in elderly patients with non-suspicious nodular disease 1

When to Repeat FNA (Not Annual)

Repeat biopsy is indicated only in specific circumstances, not on a routine annual basis:

For EU-TIRADS 5 nodules with initial benign cytology:

• Monitor every 1-2 years for 5 years, then space out if stable 1
• Repeat FNA if suspicious ultrasound changes develop or significant growth occurs 1
• The risk of malignancy remains up to 3% even after benign cytology in highly suspicious nodules 1

For EU-TIRADS 3 and 4 nodules with benign cytology:

• Repeat FNA is not recommended unless there is a change in ultrasound characteristics or significant size increase 1
• Significant growth is defined as volume increase >50% 2

For initially nondiagnostic results (Bethesda I):

• Repeat FNA after 1-3 months minimum interval 1
• If second FNA remains nondiagnostic, consider core-needle biopsy 1, 3

Long-Term Reliability of Benign Results

The evidence strongly supports conservative surveillance rather than annual biopsies:

• Long-term follow-up studies (mean 8.1 years) show only 0.85% of patients with initially benign FNA subsequently developed thyroid malignancy 4
• Only 1 of 35 patients who had more than one benign FNA result was later diagnosed with cancer 4
• Benign FNA results provide high-level long-term assurance and do not require annual re-biopsy 4

Common Pitfalls to Avoid

Do not perform routine annual biopsies on stable nodules with benign cytology—this represents overutilization and increases patient burden without improving outcomes. 1

Do not biopsy more than 2 nodules in a single patient during one session; prioritize based on EU-TIRADS score and size. 3

Do not rely on nodule size alone—always integrate ultrasound risk features into decision-making. 3

Avoid biopsying functioning nodules identified on scintigraphy that lack suspicious ultrasound features. 2, 3

Special Circumstances Requiring Closer Surveillance

Consider more frequent monitoring (though still not annual biopsy) in:

• Patients with previous head/neck irradiation 4
• Family history of thyroid cancer 4
• Growing goiter with morphological changes over time 4
• Suspicious cervical lymphadenopathy (requires immediate FNA of both nodule and node) 3

The key principle is risk-stratified, interval-based surveillance using ultrasound, with selective repeat FNA only when specific clinical or imaging criteria are met, not on an arbitrary annual schedule.